Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
I'm PortAI, I can summarize articles.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ( SIX: MOLN. NASDAQ: MOLN ) , a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ( ...
Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments